JP6978409B2 - 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン - Google Patents

抗ｔｆ抗体薬物コンジュゲートの投薬レジメン Download PDF

Info

Publication number
JP6978409B2
JP6978409B2 JP2018512876A JP2018512876A JP6978409B2 JP 6978409 B2 JP6978409 B2 JP 6978409B2 JP 2018512876 A JP2018512876 A JP 2018512876A JP 2018512876 A JP2018512876 A JP 2018512876A JP 6978409 B2 JP6978409 B2 JP 6978409B2
Authority
JP
Japan
Prior art keywords
dose
administered
adc
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532715A (ja
JP2018532715A5 (enExample
Inventor
スティーン リスバイ
ナンシー チェリー ホワイティング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2018532715A publication Critical patent/JP2018532715A/ja
Publication of JP2018532715A5 publication Critical patent/JP2018532715A5/ja
Priority to JP2021131502A priority Critical patent/JP2021181479A/ja
Application granted granted Critical
Publication of JP6978409B2 publication Critical patent/JP6978409B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018512876A 2015-09-11 2016-09-09 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン Active JP6978409B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131502A JP2021181479A (ja) 2015-09-11 2021-08-12 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217320P 2015-09-11 2015-09-11
US62/217,320 2015-09-11
PCT/EP2016/071336 WO2017042352A1 (en) 2015-09-11 2016-09-09 Dosing regimens for anti-tf-antibody drug-conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131502A Division JP2021181479A (ja) 2015-09-11 2021-08-12 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン

Publications (3)

Publication Number Publication Date
JP2018532715A JP2018532715A (ja) 2018-11-08
JP2018532715A5 JP2018532715A5 (enExample) 2019-10-17
JP6978409B2 true JP6978409B2 (ja) 2021-12-08

Family

ID=56926176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018512876A Active JP6978409B2 (ja) 2015-09-11 2016-09-09 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン
JP2021131502A Pending JP2021181479A (ja) 2015-09-11 2021-08-12 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131502A Pending JP2021181479A (ja) 2015-09-11 2021-08-12 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン

Country Status (11)

Country Link
US (2) US20190030178A1 (enExample)
EP (2) EP3919081A1 (enExample)
JP (2) JP6978409B2 (enExample)
CY (1) CY1124532T1 (enExample)
DK (1) DK3347054T3 (enExample)
ES (1) ES2877527T3 (enExample)
HU (1) HUE055109T2 (enExample)
PL (1) PL3347054T3 (enExample)
PT (1) PT3347054T (enExample)
SI (1) SI3347054T1 (enExample)
WO (1) WO2017042352A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3071237T3 (da) 2013-11-21 2024-09-09 Genmab As Lyofiliseret formulering af antistoflægemiddelkonjugat
KR20250044949A (ko) * 2017-11-02 2025-04-01 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암 치료에서의 그의 용도
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
MX2020008613A (es) * 2018-03-07 2020-09-21 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
JP2021534165A (ja) * 2018-08-16 2021-12-09 ゲンマブ エー／エス 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用
TWI844571B (zh) * 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP7406784B2 (ja) * 2019-04-17 2023-12-28 国立大学法人金沢大学 卵巣癌の検出方法
TW202131954A (zh) * 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
AU2020380732A1 (en) * 2019-11-07 2022-06-02 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2727606A3 (en) * 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA3150199C (en) 2009-01-09 2025-07-22 Seagen Inc WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE
SMT201700547T1 (it) 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
DK3071237T3 (da) 2013-11-21 2024-09-09 Genmab As Lyofiliseret formulering af antistoflægemiddelkonjugat

Also Published As

Publication number Publication date
EP3347054B1 (en) 2021-05-05
JP2021181479A (ja) 2021-11-25
PT3347054T (pt) 2021-07-15
US20220265844A1 (en) 2022-08-25
EP3919081A1 (en) 2021-12-08
ES2877527T3 (es) 2021-11-17
JP2018532715A (ja) 2018-11-08
WO2017042352A1 (en) 2017-03-16
US20190030178A1 (en) 2019-01-31
SI3347054T1 (sl) 2021-08-31
CY1124532T1 (el) 2022-07-22
HUE055109T2 (hu) 2021-11-29
EP3347054A1 (en) 2018-07-18
PL3347054T3 (pl) 2021-11-29
DK3347054T3 (da) 2021-07-19

Similar Documents

Publication Publication Date Title
JP6978409B2 (ja) 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン
JP7204651B2 (ja) 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
EP2459592B1 (en) High affinity human antibodies to human angiopoietin-2
KR102490997B1 (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
JP7681401B2 (ja) がん処置のためのａｘｌ特異的抗体
TW201726713A (zh) 最優化抗ｃｄ３雙特異性抗體及其用途
TW201402610A (zh) 抗－ｅｇｆｒ抗體及其用途
WO2021099418A1 (en) Anti-cd117 antibodies and methods of use thereof
JP2022502411A (ja) 非小細胞肺がんの処置のためのａｘｌ特異的抗体
KR20220044490A (ko) 세마포린-4d 차단(sema4d) 및 dc1 요법을 사용한 조합 요법
JP7726978B2 (ja) 抗ｃｌｄｎ－１８．２抗体及びその用途
BR112019020507A2 (pt) agente de alvejamento de erbb-2 e um anticorpo bispecífico com locais de ligação de antígenos que ligam um epítopo em uma parte extracelular de erbb-2 e erbb-3 para tratamento de um indivíduo com um tumor positivo erbb-2, erbb-2 / erbb-3
KR20230120125A (ko) Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
CN114787188A (zh) 用抗pd-1抗体治疗癌症的方法
CN116059391B (zh) 抗cldn-18.2抗体药物偶联物及其用途
RU2829637C2 (ru) Комбинированная фармацевтическая композиция для лечения опухоли
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
JP6732758B2 (ja) オレキシン受容体１型に対するヒトモノクローナル抗体
JP2018508191A (ja) オレキシン受容体１型に対するヒトモノクローナル抗体
CN108137680A (zh) 结合犬血管内皮生长因子的抗体及其在治疗犬血管生成相关疾病中的用途
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies
HK40027719A (en) Erbb-2 and erbb-3 targeting agent and bispecific antibody
BR122025018289A2 (pt) Anticorpo isolado ou fragmento de ligação a antígeno, seu uso, composição farmacêutica, molécula de polinucleotídeo isolado, vetor e célula
HK1166806B (en) High affinity human antibodies to human angiopoietin-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210812

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210812

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210916

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211111

R150 Certificate of patent or registration of utility model

Ref document number: 6978409

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250